Beyond Air Q2 net loss widens to $16.2M; guides FY2025 revenue $12-$16M

Beyond Air, Inc.

2024-Q2 EPS reported -$0.96 revenue$298,000

Revenue $0.24M vs $0 prior year; net loss $16.2M ($0.51 loss per share) vs $12.0M ($0.40) prior year.
Cash burn $16.5M ($10.1M ex one-time); cash & securities $43.9M as of Sept 30, 2023.
FY2025 revenue guidance $12M-$16M; submitted PMA supplement for cardiac surgery; CE Mark expected H1 2024.
Beyond Cancer presented positive first-in-human UNO data at SITC; VCAP trial underway, data mid-2024.
Agreement with Getz Healthcare for Asia-Pacific; Vizient Innovative Technology contract awarded.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Beyond Air, Inc. reported fiscal quarter ended September 30, 2023 results: revenue $0.24 million, net income ($16.2) million, EPS ($0.51) per share, basic and diluted.

Period: fiscal quarter ended September 30, 2023
Revenue: $0.24 million
Net income: ($16.2) million
EPS: ($0.51) per share, basic and diluted
Result: reported results

Exact text from the filing

first-in-human study for treatment of ASD in 2025 2 Financial Results for the Fiscal Quarter Ended September 30, 2023 Revenues for the three months ended September 30, 2023 were $0.24 million compared to zero for the quarter ended September 30, 2022. Cost of revenue of $0.4 million was recognized for the three months ended September 30, 2023, compared to $0.2 million

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Beyond Air, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-041878

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.